icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
SOF/VEL/VOX Results in High SVR12 Rates When Administered for 12 Weeks in DAA-Experienced Patients or for 8 Weeks in DAA-Naïve Patients: an Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Stuart K. Roberts,1 Curtis L. Cooper,2 Eric Lawitz,3 K Rajender Reddy,4 Alex J. Thompson,5 Stefan Zeuzem,6 Ira M. Jacobson,7 Peter Ruane,8 Robert H. Hyland,9 Luisa M. Stamm,9 Lingling Han,9 Diana M. Brainard,9
Norbert Bräu,10 Tarik Asselah,11 Bernard E. Willems,12 Steven L. Flamm,13 Marc Bourliere,14 Graham R. Foster,15 Edward J. Gane,16 Michael Manns,17 Stuart C. Gordon,18 Kris V. Kowdley19
1The Alfred, Melbourne, Victoria, Australia; 2Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 3Texas Liver Institute, The University of Texas Health Science Center at San Antonio, USA; 4University of Pennsylvania, Philadelphia, USA; 5St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; 6Goethe-Universität, Universitätsklinikum Frankfurt, Germany; 7Mount Sinai Beth Israel, New York, New York, USA; 8Ruane Medical & Liver Health Institute, Los Angeles, California, USA; 9Gilead Sciences, Inc., Foster City, California;
10Icahn School of Medicine at Mount Sinai, New York; 11Hopital Beaujon, Universite Paris Diderot-Paris 7, Clichy, France; 12Centre Hospitalier de l'Universite de Montreal, Quebec, Canada; 13Northwestern University, Chicago, Illinois, USA; 14Hopital Saint Joseph, Marseille, France; 15The Royal London Hospital, London, UK; 16Auckland Clinical Studies Ltd, Auckland, New Zealand; 17Medizinische Hochschule Hannover, Germany; 18Henry Ford Health System, Detroit, Michigan, USA; 19Swedish Medical Center, Seattle, Washington, USA
Gilead Triple - Sofosbuvir+valpatasvir+voxilaprevir (GS9857)
  AASLD: A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study - (11/15/16)
  AASLD: A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study - (11/15/16)
  AASLD: Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients With Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study - (11/15/16)
  AASLD: A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1-6 HCV Infection: The POLARIS-4 Study - (11/14/16)
  AASLD: Integrated Analysis of Sofosbuvir +Ribavirin, Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir for the Treatment of Genotype 4 Chronic HCV Infection - (11/15/16)